Makoto Abue

Dr. Makoto Abue

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2025 in Cancers
Verified
Journal Article
Open access
PDF file
MAMakoto Abue
Makoto Abue
MMMai Mochizuki
Mai Mochizuki
RSRie Shibuya-Takahashi
Rie Shibuya-Takahashi
KOKensuke Ota
Kensuke Ota
YWYuta Wakui
Yuta Wakui
KTKeiichi Tamai
Keiichi Tamai
Background/Objectives: The COVID-19 vaccine is a significant technological advancement with widespread global use. However, its effect on cancer immunity, particularly with repeated vaccinations, remains unclear. We aimed to investigate the relationship between repeated vaccinations and pancreatic cancer (PC) prognosis. Additionally, we examined serum IgG4 levels, known to be an immune suppressor which increases with repeated vaccinations. Methods: We retrospectively examined the effect of vaccination on survival in 272 PC patients diagnosed at our hospital from January 2018 to November 2023 and analyzed prognostic factors, including IgG4 levels in 96 PC patients. Immunohistochemistry for Foxp3 in the tumor tissue was performed, and the serum IgG4 level was measured. Serum samples from 79 patients with benign and malignant diseases, including PC, were collected between September and November 2023, and the spike-specific IgG4 level was determined using an enzyme-linked immunosorbent assay. Results: The overall survival (OS) of PC patients was shortened in those vaccinated three times or more, and the total serum IgG4 levels increased with the number of vaccinations. Of note, OS was significantly shorter in the high IgG4 group, and Foxp3-positive cells in the tumor tissues were increased. Repeated vaccinations increased the spike-specific IgG4 levels, and a positive correlation was observed between spike-specific IgG4 and the total IgG4. Conclusions: These findings highlight repeated vaccination as a poor prognostic factor in PC patients and suggest that IgG4 is induced by repeated vaccination and may be associated with a poor prognosis in these patients.

6 August 2021 in Journal of Pancreatic Cancer
Verified
Journal Article
Open access
YMYasuko Murakawa
Yasuko Murakawa
KOKazunori Ootsuka
Kazunori Ootsuka
MAMakoto Abue
Makoto Abue
Purpose: For incurable pancreatic cancer, the therapeutic goal is to prolong survival and maintain the quality of life (QOL). Unexpected outpatient consultation (OCT) and emergency hospitalization lead to QOL deterioration. The National Comprehensive Cancer Network (NCCN) guidelines recommend 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFIRINOX) and gemcitabine plus albumin-bound paclitaxel (nabPTX+GEM) as the preferred first-line regimens. Japanese clinical practice guidelines further recommend GEM and tegafur/gimeracil/oteracil potassium (S-1). Currently, no treatment strategy considers QOL at any stage during a patient's clinical course. Methods: In this study, hospital-free survival (HFS), defined as the period without hospitalization and OCT, was introduced as a new indicator of the qualitative aspect of overall survival (OS). We compared OS, length of hospitalization (LOH), OCT, and HFS for the four first-line chemotherapy groups. Results: No significant difference was observed in the median OS and HFS, nor was there a strong correlation between OS and LOH, based on the four first-line chemotherapy groups. In contrast, there were strong correlations between OS and OCT and between OS and HFS in all first-line chemotherapy groups. The ratio of OCT to OS was similar for mFOLFIRINOX and nabPTX+GEM. S-1 had the lowest OCT-to-OS ratio. The ratio of HFS to OS declined from highest to lowest in the order S-1, nabPTX+GEM, mFOLFIRINOX, and GEM. Conclusion: Our findings suggested existence of correlation differences between OS and HFS between first-line mFOLFIRINOX and first-line nabPTX+GEM. In addition, a good HFS was obtained with S-1 alone in some cases. In the future, clinical trials for chemotherapy should examine QOL during the entire clinical course.

5 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MAMakoto Abue
Makoto Abue
MMMai Mochizuki
Mai Mochizuki
RSRie Shibuya-Takahashi
Rie Shibuya-Takahashi
KOKensuke Ota
Kensuke Ota
YWYuta Wakui
Yuta Wakui
KTKeiichi Tamai
Keiichi Tamai
The COVID-19 vaccine is a significant technological advancement with widespread global use. However, its effect on cancer immunity, particularly with repeated vac-cinations, remains unclear. We aimed to investigate the relationship between repeated vaccinations and pancreatic cancer (PC) prognosis. Additionally, we examined serum IgG4 levels, known to be an immune suppressor and increased with repeated vac-cinations. Methods: We retrospectively examined the effect of vaccination on survival in 272 PC patients diagnosed at our hospital from January 2018 to November 2023 and analyzed prognostic factors, including IgG4 levels in 96 PC patients. Immunohisto-chemistry for Foxp3 in the tumor tissue was performed and serum IgG4 level was measured. Serum samples from 79 patients with benign and malignant diseases, in-cluding PC, were collected between September and November 2023, and spike-specific IgG4 level was determined using enzyme-linked immunosorbent assay. Results: The overall survival (OS) of PC patients was shortened in those vaccinated three times or more, and the total serum IgG4 levels increased with the number of vaccinations. Of note, OS was significantly shorter in the high IgG4 group, and Foxp3-positive cells in the tumor tissues were increased. Repeated vaccinations in-creased spike-specific IgG4 levels, and a positive correlation was observed between spike-specific IgG4 and total IgG4. Conclusions: These findings highlight repeated vaccination as a poor prognostic factor in PC patients and suggest that IgG4 is induced by repeated vaccination and may be associated with a poor prognosis in these pa-tients.

27 October 2026 in Cancers
Verified
Journal Article
Open access
PDF file
MAMakoto Abue
Makoto Abue
NANaoki Asano
Naoki Asano
TMTakanori Morikawa
Takanori Morikawa
Atsushi MasamuneAtsushi Masamune
Atsushi Masamune
SNSatoshi Nishizuka
Satoshi Nishizuka
JYJun Yasuda
Jun Yasuda
Background/Objectives: Circulating tumor DNA (ctDNA) provides molecular information at different stages of the pancreatic ductal adenocarcinoma (PDAC) patient journey, but its clinical value differs according to when and why it is measured. This narrative review examines ctDNA from diagnosis and molecular profiling through neoadjuvant therapy, postoperative molecular residual disease (MRD), surveillance, and dynamic monitoring during systemic therapy, critically assessing the strength and limitations of the evidence at each clinical stage and its implications for clinical decision-making. Methods: Relevant studies were identified primarily through PubMed/MEDLINE, supplemented by forward citation tracking in Google Scholar, backward reference screening, and ClinicalTrials.gov searches for ongoing interventional studies. Original PDAC clinical studies were prioritized, with selected reviews, guidelines, consensus statements, and position papers used for context. Results: In localized disease, limited ctDNA shedding constrains diagnostic sensitivity, although baseline detection may provide prognostic information. After surgery, ctDNA positivity consistently identifies patients at increased risk of recurrence, whereas a negative result cannot reliably exclude residual disease. During surveillance, newly detectable or rising ctDNA may precede radiological recurrence. In advanced disease, serial ctDNA kinetics provide increasingly consistent information on treatment response and progression. Evidence for dynamic monitoring is increasing, but evidence that ctDNA-guided treatment or surveillance improves patient outcomes remains insufficient. Conclusions: The clinical value of ctDNA depends on when and why it is measured. ctDNA should complement rather than replace conventional assessments. By distinguishing established prognostic associations from emerging monitoring applications and unproven ctDNA-guided interventions, this review provides a practical framework for interpreting ctDNA across the PDAC patient journey. Prospective trials are needed to determine whether ctDNA-guided decisions improve patient outcomes.

1 October 2011
Verified
Journal Article
Closed access
MAMakoto Abue
Makoto Abue
MSMasaki Suzuki
Masaki Suzuki
TMTakefumi Miyazaki
Takefumi Miyazaki
ENEiki Nomura
Eiki Nomura
KUKiyoshi Uchimi
Kiyoshi Uchimi
ISIkuro Sato
Ikuro Sato

1 January 2022
Verified
Journal Article
Closed access
KOKensuke Ota
Kensuke Ota
MAMakoto Abue
Makoto Abue
RMRiku Meguro
Riku Meguro
JKJun Kusaka
Jun Kusaka
WIWataru Iwai
Wataru Iwai
ISIkurou Sato
Ikurou Sato